Overview
VYGR market data
Price History
VYGR price chart · 3M
- O
- 3.47
- H
- 3.52
- L
- 3.43
- C
- 3.49
- Vol
- 14,565.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $3.47
- Previous Close
- $3.46
- Day High
- $3.52
- Day Low
- $3.43
- 52 Week High
- $4.46
- 52 Week Low
- $2.94
- 7 Day Return
- +5.12%
- 30 Day Return
- +14.80%
- 90 Day Return
- -9.82%
- 1 Year Return
- -4.38%
- Daily Notional Volume
- $50.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -312.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.94 – $5.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $193.3M · P/B 1.11 · P/S 5.61.
Company News
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price TargetBenzinga · Aug 10, 2026, 10:58 AM
Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M EstimateBenzinga · Aug 6, 2026, 10:03 PM
8-K filing — Voyager Therapeutics, Inc. (VYGR)SEC EDGAR · Jul 13, 2026, 12:44 PM
Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In PrimatesBenzinga · Jul 13, 2026, 12:10 PM
Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial StockBenzinga · Jul 1, 2026, 11:55 AM
Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's DiseaseBenzinga · Jun 1, 2026, 12:02 PM